Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

Leronlimab has the best chance

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ScienceOC Member Profile
Followed By 2
Posts 59
Boards Moderated 0
Alias Born 05/06/20
160x600 placeholder
CEO Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 5/10/2021 7:00:00 AM
CytoDyn to conduct two COVID-19 trials in Brazil Seeking Alpha - 5/5/2021 6:25:40 AM
CytoDyn provides updates on leronlimab HIV extension arm; to hold webcast on May 5 on multiple initiatives Seeking Alpha - 5/3/2021 9:46:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2021 4:32:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 6:28:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/21/2021 4:31:54 PM
CytoDyn initiates rolling submission of leronlimab in COVID-19 to Canada regulator Seeking Alpha - 4/19/2021 6:54:58 AM
CytoDyn executes supply and distribution agreement with Chiral Pharma Seeking Alpha - 4/15/2021 9:34:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/12/2021 4:31:04 PM
CytoDyn completes enrollment in COVID-19 long-hauler trial Seeking Alpha - 4/9/2021 6:59:31 AM
CytoDyn updates on leronlimab-treated COVID-19 patient Seeking Alpha - 4/5/2021 11:51:19 AM
CytoDyn to provide full update on its activities on April 6 Seeking Alpha - 4/1/2021 6:19:48 AM
CytoDyn files new protocol with FDA for 4 doses of leronlimab for critical COVID-19 Seeking Alpha - 4/1/2021 6:13:14 AM
CytoDyn’s leronlimab reduces mortality by 82% at 14 days in critically ill COVID-19 patients Seeking Alpha - 3/30/2021 7:08:56 AM
Philippines OKs use of CytoDyn's leronlimab in COVID-19 Seeking Alpha - 3/29/2021 6:30:52 AM
Nextech AR (OTCQB: NEXCF) Doubling Sales - Emerging Growth Report InvestorsHub NewsWire - 3/24/2021 6:45:37 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 3/18/2021 7:46:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/16/2021 8:31:13 AM
CytoDyn promotes from within for COO role Seeking Alpha - 3/16/2021 6:03:45 AM
Nextech AR (OTCQB: NEXCF) $13 million Deal, The Next Short Squeeze InvestorsHub NewsWire - 3/11/2021 7:53:20 AM
Enrollment underway in CytoDyn’s long-haulers COVID-19 trial Seeking Alpha - 3/11/2021 5:49:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/8/2021 5:28:38 PM
CytoDyn to release CD12 trial data on March 8 Seeking Alpha - 3/8/2021 6:34:51 AM
CytoDyn to file for rolling review of leronlimab in COVID-19 in U.S., U.K. and Canada Seeking Alpha - 3/7/2021 11:56:10 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/3/2021 5:23:39 PM
ScienceOC   Saturday, 05/23/20 07:44:39 PM
Re: None
Post # of 164724 
Leronlimab has the best chance

So far:
1) Remdesivir is not much of treatment in my mind (after reading the article from NEJM)
2) No vaccine in sight, there r talks but nothing concrete in the horizon, and will take months to years before coming out
3) Even with vaccine or anti-viral, still need treatment
4) Even though anecdotal, leronlimab looks promising. I cannot wait till the preliminary data comes out soon from several clinical trials , maybe and hopefully next week
5) Mexico and China might start using leronlimab soon or started already
6) If leronlimab shows positive in Mexico, this will spread to Central and South America, which is now the epicenter of the world fpr COVID-19
7) Leronlimab may be helpful for bunch of other diseases
8) BLA submitted to FDA for HIV treatment

Not sure how high it will go. Probably better to ask Black-Ops for that!

Politics and big pharma may get in the way but Science will always wins.

I think I am going to buys some shares on Tuesday!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences